Published in Cancer Weekly, November 23rd, 2010
"These compounds were fully characterized using IR, NMR spectroscopic techniques, and elemental analysis. Mechanisms for the formation of the chroman moiety of these compounds were also proposed," wrote Y. Tang and colleagues, Nanchang University.
The researchers concluded: "MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to estimate their cytotoxicity toward two cancer cell lines: human ovarian cancer (A2780) and human cervical cancer (Hela)."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.